Mold-Tek Packaging has closed the financial year 2025 with growth of around 11.8% in sales and 7% in EBITDA while profit after tax came down by around 9% due to high provision in depreciation and financial costs. Q4FY25 has been a landmark year for the company with the pharmaceutical division having crossed breakeven point and resulting in Mold-Tek making profits for the first time.
The management expects that the pharma division will continue to do extremely well in FY26 as new products are continuously being added to the pharma segment. Another positive development is the 6.8% growth in the paint segment for the current financial year , which augurs well for the company’s financial position in FY26. The pharmaceutical division has been posting around Rs 2.30 crores per month of sales enabling it to reach Rs 6.70 crores for only Q4 FY25 but going forward the company is expecting Rs 30 crores of volume sales for the full financial year 2026 on the back of new Pharma products being launched in the country and probably Rs 50 crores for FY27.
The company is expecting all the machines of the injection moulding category to be in place by June 2025 thereby contributing to three times top line growth for FY26 on the back of huge demand from pharma companies who have started buying commercially in the upcoming quarters. Mold-Tek Packaging is extremely bullish on the pharma packaging industry due to expansion in the sector plus is also purchasing additional property to its existing facility in Sultanpur , Hyderabad for about Rs 10 crores for future expansion in the aforesaid segment. This would result in turnover doubling from currently 1500 tons to 3000 tons and Rs 100 crores revenue by end of FY26.
The paint division has also turned the corner by posting only 2.7% growth improvement during Q4FY25 but Mold-Tek is expecting a double digit growth over the next few quarters. These can come due to support from the large corporates , Aditya Birla group and Asian Paints by adding new capacities and shifting fresh business to Mold-Tek Packaging . The company management is also quite optimistic on the pharmaceutical and paint industry for the financial year 2025-26 and expects a big jump in the Food and FMCG business. This optimism stems due to the Panipat food and FMCG production starting in June 2025 which will add to new clients and solid revenue uptick .
The large clients recently added in the Food and FMCG segment are Mankind Pharma and Marico . The company is estimating a capital expenditure budget of around Rs 75-80 crores for the financial year ending 2026. Brokers and Analysts are bullish on the Mold-Tek Packaging scrip and expect the stock to double over the next 18 months time frame on the back of revenue and profit doubling in the aforesaid period . The Mold-Tek Packaging stock is currently quoting at Rs 696 on the bourses and portfolio investors can accumulate the scrip for solid gains over long term .